Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Dr. Thurin joined the DCTD in 2001 as a program director.  Her major focus has been on development and validation of biomarkers for clinical application in cancer.

Dr. Thurin plays a central role in the Cancer Immune Monitoring and Analysis Center and Immunological Data Commons (CIMAC-CIDC) Network, which works jointly with the Public Private Partnership (PACT) supported by the NCI and industrial partners via the Foundation for NIH (FNIH). 

CIMAC-CIDC-PACT Network's focus is on correlative study in over 40 clinical trials in immunotherapy. The Network generates comprehensive profiles of tumors, the tumor microenvironment, and hosts, using state-of-the art multiparametric approaches to identify biomarkers of response, resistance, and toxicity. The Network contributes to publicly accessible database of clinically annotated immune oncology biomarker data in the NCI Cancer Research Data Commons (CRDC). 

Her research at The Wistar Institute in Philadelphia, PA focused on the structural and functional characterization of carbohydrate antigens (Ag) in cancer. These studies succeeded in identification of multiple antigens including the first glycolipid tumor-associated antigen, sialyl Lewis A (SLea), known as CA19-9 for monitoring of pancreatic and colon cancer. The SLea antigen is detected by the serological assay CA 19–9, which was approved by the FDA to manage patients with pancreatic cancer and monitor their therapeutic responses and disease progression.

Dr. Thurin significantly contributed to the initiative to promote and incorporate the ‘Immunoscore’ into routine clinical settings. This provides prognostic and predictive tumor agnostic biomarker to define immune fitness of a tumor and stratify patients who will benefit from immune therapies.

She has authored over 100 papers in peer-reviewed journals.

Education

  • Ph.D. and M.S., Biochemistry, University of Warsaw, Poland
  • Postdoctoral training at the Wistar Institute of Anatomy & Biology, Philadelphia, PA
  • Updated:
Email